PUBLISHER: Grand View Research | PRODUCT CODE: 1611108
PUBLISHER: Grand View Research | PRODUCT CODE: 1611108
The U.S. peripheral nerve injuries market size is estimated to reach USD 712.5 million by 2030, registering a CAGR of 7.4% from 2025 to 2030, according to a new report by Grand View Research, Inc. The growth of the market is due to increasing healthcare expenditure in the U.S., an increasing prevalence of peripheral nerve injuries, growing focus on research and development, and a growing patient preference for minimally invasive procedures.
Technological advancements are revolutionizing the field of peripheral nerve injury treatment in the U.S. New and innovative treatment options such as nerve grafts, nerve conduits, and neurostimulation devices are providing improved outcomes and helping patients recover faster. Additionally, the use of minimally invasive surgical techniques, such as end-to-end nerve sutures and nerve decompression procedures, is gaining popularity among patients due to their benefits of faster recovery times. These advancements in medical technology are driving the growth of the market by providing more effective and less invasive treatment options.
Investments from key market players and collaborations between academia, industry, and healthcare institutions are driving R&D efforts, leading to the discovery of new treatment modalities. For instance, in June 2022, Vascudyne, Inc., a leading biotechnology company in regenerative medicine, was awarded a grant from Regenerative Medicine Minnesota for a research study titled "Production of a Peripheral Nerve Wrap Using Tissue Tubes from Regenerative Engineering." The study will be funded with USD 100,000 for one year, starting in June 2022, and will utilize Vascudyne's TRUE Tissue technology.
The COVID-19 pandemic has boosted the demand for minimally invasive procedures as it offer benefits such as shorter recovery times, potentially lower costs, better treatment options, and integration with telemedicine technologies. These factors may impact the market for U.S. peripheral nerve injuries positively.